Treatment schema for Children's Cancer Group 1962
| Induction | |
| Vincristine IV | 1.5 mg/m2 days 0, 7, 14, 21 |
| Prednisone PO | 40 mg/m2 days 0-28 then 10 day taper |
| Pegaspargase IM | 2500 IU/m2 day 3 |
| or native asparaginase IM | 6000 IU/m2 days 3, 5, 8, 10, 12, 15, 17, 19, 22 |
| Cytarabine IT | 30 mg, 50 mg, or 70 mg day 0* |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg days 7, 28* |
| Consolidation | |
| Vincristine IV | 1.5 mg/m2 days 0, 28, 56 |
| 6-mercaptopurine PO | 75 mg/m2 days 1-28 |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg days 7, 14, 21* |
| Interim maintenance no. 1 and no. 2 | |
| Vincristine IV | 1.5 mg/m2 days 0, 28 |
| Prednisone PO | 40 mg/m2 days 0-4, 28-32 |
| Methotrexate PO | 20 mg/m2 weekly |
| 6-mercaptopurine PO | 75 mg/m2 daily |
| Delayed intensification no. 1 and no. 2 | |
| Vincristine IV | 1.5 mg/m2 days 0, 7, 14 |
| Dexamethasone PO | 10 mg/m2 days 0-6, 14-20 |
| Pegaspargase IM | 2500 IU/m2 day 3 |
| or native asparaginase IM | 6000 IU/m2 days 3, 5, 8, 10, 12, 15 |
| Doxorubicin IV | 25 mg/m2 days 0, 7, 14 |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg days 0, 28, 35* |
| Cyclophosphamide IV | 1000 mg/m2 day 28 |
| Cytarabine IV or SC | 75 mg/m2 days 29-32, 36-39 |
| Thioguanine PO | 60 mg/m2 days 28-41 |
| Maintenance | |
| Vincristine IV | 1.5 mg/m2 every 4 weeks |
| Prednisone PO | 40 mg/m2 days 0-4 every 4 weeks |
| Methotrexate PO | 20 mg/m2 weekly |
| 6-mercaptopurine PO | 75 mg/m2 daily |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg every 3 months* |
| Induction | |
| Vincristine IV | 1.5 mg/m2 days 0, 7, 14, 21 |
| Prednisone PO | 40 mg/m2 days 0-28 then 10 day taper |
| Pegaspargase IM | 2500 IU/m2 day 3 |
| or native asparaginase IM | 6000 IU/m2 days 3, 5, 8, 10, 12, 15, 17, 19, 22 |
| Cytarabine IT | 30 mg, 50 mg, or 70 mg day 0* |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg days 7, 28* |
| Consolidation | |
| Vincristine IV | 1.5 mg/m2 days 0, 28, 56 |
| 6-mercaptopurine PO | 75 mg/m2 days 1-28 |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg days 7, 14, 21* |
| Interim maintenance no. 1 and no. 2 | |
| Vincristine IV | 1.5 mg/m2 days 0, 28 |
| Prednisone PO | 40 mg/m2 days 0-4, 28-32 |
| Methotrexate PO | 20 mg/m2 weekly |
| 6-mercaptopurine PO | 75 mg/m2 daily |
| Delayed intensification no. 1 and no. 2 | |
| Vincristine IV | 1.5 mg/m2 days 0, 7, 14 |
| Dexamethasone PO | 10 mg/m2 days 0-6, 14-20 |
| Pegaspargase IM | 2500 IU/m2 day 3 |
| or native asparaginase IM | 6000 IU/m2 days 3, 5, 8, 10, 12, 15 |
| Doxorubicin IV | 25 mg/m2 days 0, 7, 14 |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg days 0, 28, 35* |
| Cyclophosphamide IV | 1000 mg/m2 day 28 |
| Cytarabine IV or SC | 75 mg/m2 days 29-32, 36-39 |
| Thioguanine PO | 60 mg/m2 days 28-41 |
| Maintenance | |
| Vincristine IV | 1.5 mg/m2 every 4 weeks |
| Prednisone PO | 40 mg/m2 days 0-4 every 4 weeks |
| Methotrexate PO | 20 mg/m2 weekly |
| 6-mercaptopurine PO | 75 mg/m2 daily |
| Methotrexate IT | 8 mg, 10 mg, or 12 mg every 3 months* |
The dose of IT medications was based on age.
IV indicates intravenously; PO, oral; IM, intramuscularly; IT, intrathecal; and SC, subcutaneous.